Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntelligent Ultrasound Regulatory News (IUG)

  • This share is currently suspended. It was suspended at a price of 12.875
  • There is currently no data for IUG

Trading Update

24 Jul 2023 07:00

RNS Number : 8680G
Intelligent Ultrasound Group PLC
24 July 2023
 

 

24 July 2023

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.

 

 

Intelligent Ultrasound Group plc

(the "Group")

 

Trading update

 

Intelligent Ultrasound Group plc reports positive trading period in H1

 

Intelligent Ultrasound Group plc (AIM: IUG) ("Intelligent Ultrasound" or "the Group"), the 'classroom to clinic' ultrasound company specialising in artificial intelligence (AI) software and simulation, today provides a trading update for the six months to 30 June 2023.

 

Financial highlights:

· The Group expects to report that revenue for the period to 30 June 2023 has grown by 3% to £6.1m (H1 2022: £5.9m)

H1 2022 revenue figures included £1.4m of one-off orders from the NHS in the UK, so on an adjusted like-for-like basis, revenue in H1 2023 is expected to have increased by 35% (H1 2022 adjusted: £4.5m)

· The Group's clinical AI products continue to gain traction and revenues are expected to have more than doubled to £0.7m (H1 2022: £0.3m)

· Cash at bank on 30 June 2023 was £3.4m (31 December 2022: £7.2m), impacted by working capital seasonality in H1

· Cash utilisation in H2 is expected to be materially lower and the Group remains on target to reach profitability with its current cash

 

The company will publish its half-year results in August.

 

 

For further information, please contact:

 

Intelligent Ultrasound Group plc 

www.intelligentultrasound.com

Stuart Gall, CEO 

Tel: +44 (0)29 2075 6534 

Helen Jones, CFO

 

 

Cenkos Securities - Nominated Advisor and Broker

Giles Balleny/Max Gould (Corporate Finance)

Tel: +44 (0)20 7397 8900 

Michael Johnson/Julian Morse (Sales) 

TB Cardew - PR Advisors

Ed Orlebar

Intelligentultrasound@tbcardew.com

Tel: +44 (0)7738 724630

Allison Connolly

Tel: +44 (0)7587 453955

Emma Pascoe-Watson

Tel: +44 (0)7774 620415

Hero Kurzeja

Tel: +44 (0)7827 130430

 

 

About Intelligent Ultrasound Group

 

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

 

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,500 simulators have been sold to over 750 medical institutions around the world.

 

Clinical AI software

 

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

 

www.intelligentultrasound.com

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA, but is not available for sale in any other territory requiring government approval for this type of product.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEDDFILFIV
Date   Source Headline
30th May 20227:00 amRNSNotice of AGM and 2021 Report and Accounts
3rd May 20227:00 amRNSFinal Results
28th Apr 20227:00 amRNSInvestor presentation
25th Apr 20227:00 amRNSNotice of Results
25th Jan 20227:00 amRNSAdditional product agreement with GE Healthcare
13th Jan 20228:12 amRNS2021 Full Year Trading Update
15th Sep 20217:00 amRNSDirectorate Change
19th Aug 20217:00 amRNSHalf-year Report
11th Aug 20217:00 amRNSNotice of Results
14th Jul 20217:00 amRNSExercise of warrants and total voting rights
14th Jul 20217:00 amRNSTrading update
22nd Jun 20215:13 pmRNSResult of AGM
24th May 20219:09 amRNSNotice of AGM
19th May 20217:00 amRNSAppointment of Ingeborg Øie to Board
4th May 20217:00 amRNSUK launch of ScanNav Anatomy: PNB
29th Apr 20217:00 amRNSFinal Results
28th Apr 20217:00 amRNSNotice of Results
14th Apr 20217:00 amRNSUpdate on preliminary results
13th Apr 20217:00 amRNSCE approval of ScanNav Anatomy: PNB
8th Apr 20217:00 amRNSConference attendance
26th Mar 20217:00 amRNSNotice of Results
10th Mar 20217:00 amRNSLaunch of ScanNav Anatomy: PNB Trainer
4th Mar 20217:00 amRNSInstallation of 1000th Simulation System
12th Jan 20217:00 amRNSTrading update
22nd Dec 202010:28 amRNSGrant of share options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.